Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$119.96 USD
-2.88 (-2.35%)
Updated Jun 17, 2024 11:28 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 441 - 460 ( 662 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
No Surprises - Consistent Evidence of Etepliersen''s Clinical Benefit
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expectations Heading into Conference Call on 10/1/15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fourth Biopsy Could Lay the Foundation for Future "Class Approvals"
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Shapeshifting Bears Back to Where It Started, Small N
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Bear Thesis Bites the Dust, Target to $50
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen NDA Accepted, All Eyes on Advisory Committee Meetings Later this Year; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen NDA Accepted, All Eyes on Advisory Committee Meetings Later this Year; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flibanserin Approval a Sign of Regulatory Flexibility - DMD Lives Matter
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L